Searchable abstracts of presentations at key conferences in endocrinology

ea0011p435 | Endocrine disruptors | ECE2006

Endocrine disruptors and idiopathic gynecomastia with aromatase gene polymorphism

Czajka IK , Zgliczynski S , Zgliczynski W

Gynecomastia is a benign enlargement of the male breast due to the imbalance between androgens and estrogens in the breast tissue. In up to 40% of cases no evident reasons could be found. This idiopathic gynecomastia may be caused by excess aromatisation within breast tissue. Aromatase is a key enzyme in estrogen biosynthesis. Mutations and polymorphisms of aromatase gene could lead to its overexpression. Some endocrine disruptors - chemicals that interfere with hormone functi...

ea0011oc52 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

In acromegaly bone mineral density depends on gonadal function

Kochman M , Zgliczynski W , Misiorowski W , Zdunowski P , Papierska L , Zgliczynski S

The aim of the study was to evaluate factors determining bone mineral density (BMD) and serum concentrations of osteocalcin (OC) and carboxyterminal telopeptide of type I collagen (ICTP) in acromegaly. Material consisted of 121 patients with active acromegaly, aged 23–80 years. In the whole group BMD, assessed by DXA, was: 0.35±0.15 at L2–L4, 0.60±0.11 at femoral neck, 0.05±0.12 at Ward’s triangle and 0.59±0.13 at trocha...

ea0011p902 | Thyroid | ECE2006

Corticotherapy alone or corticotherapy combined with orbital radiotherapy in severe active Graves’ ophthalmopathy: therapeutic outcome in 905 patients

Jastrzebska H , Gietka-Czernel M , Janik J , Zgliczynski S , Karczmarzyk R , Fijuth J

The aim of the study was to compare efficacy and tolerability of systemic corticotherapy alone to corticotherapy combined with orbital radiotherapy in severe active Graves’ ophthalmopathy. We studied 905 patients, aged 35–73 years (mean 58.2 ±12), with clinical activity score above 4 and ATA class 3c to 6. Therapeutic outcome was assessed by change in ophthalmopathy index. For 4 weeks all subjects received corticotherapy: 869 - oral prednisone 60–100 mg dai...